Understanding the risks of thrombosis in CALR-mutated MPN patients
Evaluation of the Pathobiology of CALR-mutated MPN Cells
This study is trying to understand why people with CALR mutations in myeloproliferative neoplasms have a different risk of blood clots compared to those with JAK2 mutations by looking at certain blood markers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 35 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 2 sites (Charlotte, North Carolina and 1 other locations) |
| Trial ID | NCT06480591 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the expression levels of TLR 2 and TLR 4 on mononuclear cells in patients with CALR mutation-positive myeloproliferative neoplasms (MPN) and compare these levels to those in patients with JAK2 V617F mutations and healthy controls. Participants will provide blood samples during standard care blood draws, and their demographic and clinical data will be collected. The study seeks to uncover the underlying reasons for the increased risk of thrombosis in patients with JAK2 mutations compared to those with CALR mutations. It will initially be conducted at a single center, the Wake Forest Baptist Comprehensive Cancer Center.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of myeloproliferative neoplasm and a CALR-positive genetic mutation.
Not a fit: Patients with MPN who have a JAK2 V617F mutation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the mechanisms behind thrombosis risk in MPN patients, potentially leading to improved management strategies.
How similar studies have performed: While this study focuses on CALR mutations, similar studies evaluating the pathobiology of MPNs have shown promising results, suggesting that understanding these mechanisms can lead to better patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR). * Age ≥ 18 years at the time of enrollment * Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs * CALR-positive genetic mutation Exclusion Criteria: \- Diagnosis of MPN with JAK2 V617F mutation
Where this trial is running
Charlotte, North Carolina and 1 other locations
- Atrium Health Levine Cancer — Charlotte, North Carolina, United States (Recruiting)
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Aleksander Chojecki, MD — Atrium Health Levine Cancer
- Study coordinator: Courtney Schepel
- Email: Courtney.Schepel@atriumhealth.org
- Phone: (980) 292-0817
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.